BR112016007328A2 - composições oftálmicas baseadas em epinefrina para administração intraocular e métodos para fabricar as mesmas - Google Patents

composições oftálmicas baseadas em epinefrina para administração intraocular e métodos para fabricar as mesmas

Info

Publication number
BR112016007328A2
BR112016007328A2 BR112016007328A BR112016007328A BR112016007328A2 BR 112016007328 A2 BR112016007328 A2 BR 112016007328A2 BR 112016007328 A BR112016007328 A BR 112016007328A BR 112016007328 A BR112016007328 A BR 112016007328A BR 112016007328 A2 BR112016007328 A2 BR 112016007328A2
Authority
BR
Brazil
Prior art keywords
epinephrine
methods
compositions
based ophthalmic
ophthalmic compositions
Prior art date
Application number
BR112016007328A
Other languages
English (en)
Inventor
Scott KAROLCHYK John
L Baum Mark
Original Assignee
Imprimis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imprimis Pharmaceuticals Inc filed Critical Imprimis Pharmaceuticals Inc
Publication of BR112016007328A2 publication Critical patent/BR112016007328A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D25/00—Details of other kinds or types of rigid or semi-rigid containers
    • B65D25/02—Internal fittings
    • B65D25/04—Partitions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Mechanical Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo composições oftálmicas baseadas em epinefrina para administração intraocular e métodos para fabricar as mesmas composições farmacêuticas para injeção intraocular são descritas, as com-posições compreendem uma quantidade terapeuticamente eficaz de epinefrina ou adrenalina livre de conservante e livre de sulfito liofilizada e um quelante de metal. métodos para fabricar as composições e usar as mesmas para injeções intraocula-res também são descritos.
BR112016007328A 2013-10-03 2014-10-03 composições oftálmicas baseadas em epinefrina para administração intraocular e métodos para fabricar as mesmas BR112016007328A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361886269P 2013-10-03 2013-10-03
US201361892872P 2013-10-18 2013-10-18
US201461947778P 2014-03-04 2014-03-04
PCT/US2014/059077 WO2015051264A1 (en) 2013-10-03 2014-10-03 Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricatiing thereof

Publications (1)

Publication Number Publication Date
BR112016007328A2 true BR112016007328A2 (pt) 2017-08-01

Family

ID=52779188

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007328A BR112016007328A2 (pt) 2013-10-03 2014-10-03 composições oftálmicas baseadas em epinefrina para administração intraocular e métodos para fabricar as mesmas

Country Status (10)

Country Link
US (4) US10993921B2 (pt)
EP (1) EP3052095A4 (pt)
JP (2) JP2016532723A (pt)
KR (1) KR20160070077A (pt)
AU (2) AU2014329412B2 (pt)
BR (1) BR112016007328A2 (pt)
CA (1) CA2925008A1 (pt)
IL (1) IL244687A0 (pt)
MX (1) MX2016004257A (pt)
WO (1) WO2015051264A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016004257A (es) 2013-10-03 2016-08-17 Imprimis Pharmaceuticals Inc Composiciones oftalmicas basadas en epinefrina para la administracion intraocular y metodos para su frabricacion.
TWI705812B (zh) * 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
US20170189352A1 (en) 2015-03-13 2017-07-06 Par Pharmaceutical, Inc. Epinephrine formulations
US20190350881A1 (en) * 2016-06-17 2019-11-21 Ys Pharmtech Stabilization of epinephrine formulations
KR20190035927A (ko) 2016-08-25 2019-04-03 임프리미스 파마슈티컬스, 인크. 안구 내 투여를 위한 에피네프린-기반 안과용 조성물 및 이의 제조방법
US20180318319A1 (en) 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
US11925608B2 (en) * 2017-09-26 2024-03-12 Ys Pharmtech Stabilization of epinephrine formulations
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
US10653646B2 (en) 2018-03-23 2020-05-19 Nevakar Inc. Epinephrine compositions and containers
US11071724B2 (en) 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
US20230277694A1 (en) * 2022-03-04 2023-09-07 Harrow Ip, Llc Ophthalmic dye composition and method for administering same

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3808317A (en) * 1969-10-29 1974-04-30 Alcon Labor Inc Stabilized aqueous borate complexes of biologically active catechol amines
US4590210A (en) * 1979-03-09 1986-05-20 Langham Maurice E Compositions for treatment of ocular hypertension
US4525346A (en) * 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4550022A (en) * 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
CA2002643A1 (en) * 1988-11-09 1990-05-09 Maryjane Helenek Antioxidant-free epinephrine solution for ophthalmic use
NL9102148A (nl) * 1991-12-20 1993-07-16 Dsm Nv Copolymeer van lacton en carbonaat en werkwijze voor het verkrijgen ervan.
AU5405894A (en) * 1992-10-21 1994-05-09 Alcon Laboratories, Inc. Composition for irrigating intraocular tissues and maintaining mydriasis during intraocular surgery
US5654337A (en) 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
US5709852A (en) 1995-12-05 1998-01-20 Basf Corporation Ethylene oxide/propylene oxide/ethylene oxide (EO/PO/EO) triblock copolymer carrier blends
WO1998003641A1 (en) 1996-07-23 1998-01-29 Crandall Wilson T Transdermal transport of molecules
FR2779061B1 (fr) * 1998-04-14 2004-08-20 Pharmatop Nouveau procede de stabilisation de composes phenoliques et les compositions pharmaceutiques en resultant
DE19859427A1 (de) 1998-12-22 2000-06-29 Beiersdorf Ag Kosmetische oder pharmazeutische lecithinhaltige Gele oder niedrigviskose, lecithinhaltige O/W-Mikroemulsionen
CA2362260C (en) * 1999-02-16 2009-05-12 Michael A. Taylor Single dose delivery device
EP1326642A2 (en) * 2000-09-29 2003-07-16 Board of Trustees operating Michigan State University Catecholamine pharmaceutical compositions and methods
FR2833493B1 (fr) * 2001-12-18 2005-09-23 Ioltechnologie Production Forme galenique solide et soluble pour l'administration occulaire de principes actifs et procede de fabrication d'un insert ophtalmique solide et soluble
SI1531794T1 (sl) 2002-06-28 2017-12-29 Civitas Therapeteutics, Inc. Epinefrin za vdihavanje
US20040072809A1 (en) * 2002-07-30 2004-04-15 Omeros Corporation Ophthalmologic irrigation solutions and method
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US20050176823A1 (en) 2004-02-10 2005-08-11 Diaz Robert L. Intra-operative procedure for post-operative pain control
FR2882930B1 (fr) 2005-03-09 2009-03-27 Walid Katib Nouvelles compositions ophtalmologiques et leur mode d'utilisation
DE102005038368A1 (de) 2005-08-13 2007-02-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Doppelkammer-Behälter zur Lyophilisation, Verfahren zu dessen Befüllung und dessen Verwendung
US20070196324A1 (en) 2006-02-01 2007-08-23 Keefe Candace R Cellulite skin treatment methods and compositions
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20080269347A1 (en) * 2006-09-28 2008-10-30 Azopharma, Inc. Epinephrine formulations
US20090017120A1 (en) 2007-03-23 2009-01-15 Humco Holding Group, Inc. Phase stable lecithin organogel composition
US8323695B2 (en) 2007-08-13 2012-12-04 Mcneil-Ppc, Inc. Method for stabilizing phenylephrine
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
CN105532922A (zh) 2008-11-14 2016-05-04 阿彻丹尼尔斯米德兰德公司 有机凝胶组合物及其生产方法
CN101444481A (zh) 2009-01-06 2009-06-03 河北科技大学 不含抑菌剂的托吡卡胺滴眼液及其制备方法
PT2437782E (pt) 2009-06-04 2013-10-30 Alk Ag Composição estabilizada que compreende pelo menos um composto adrenérgico
US20130210840A1 (en) 2010-06-11 2013-08-15 Imprimis Pharmaceuticals, Inc. Anti-Cellulite Composition and Method of Treating Cellulite
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
KR20140112825A (ko) 2013-03-14 2014-09-24 삼성전자주식회사 전자 장치의 전자 결제 방법 및 장치
CA2915814A1 (en) 2013-06-18 2014-12-24 Imprimis Pharmaceuticals Inc. Local use of pentoxifylline to treat peyronie's disease
US9301936B2 (en) 2013-07-08 2016-04-05 Imprimis Pharmaceuticals, Inc. Pharmaceutical formulations of tranexamic acid and their use
MX2016004257A (es) 2013-10-03 2016-08-17 Imprimis Pharmaceuticals Inc Composiciones oftalmicas basadas en epinefrina para la administracion intraocular y metodos para su frabricacion.
KR20190035927A (ko) 2016-08-25 2019-04-03 임프리미스 파마슈티컬스, 인크. 안구 내 투여를 위한 에피네프린-기반 안과용 조성물 및 이의 제조방법

Also Published As

Publication number Publication date
US20160354308A1 (en) 2016-12-08
CA2925008A1 (en) 2015-04-09
MX2016004257A (es) 2016-08-17
JP2016532723A (ja) 2016-10-20
IL244687A0 (en) 2016-04-21
US20210275471A1 (en) 2021-09-09
EP3052095A4 (en) 2017-07-05
US10993921B2 (en) 2021-05-04
AU2014329412B2 (en) 2020-02-27
WO2015051264A8 (en) 2016-04-07
US20150119440A1 (en) 2015-04-30
JP2019142964A (ja) 2019-08-29
AU2014329412A1 (en) 2016-05-05
US20170049721A1 (en) 2017-02-23
WO2015051264A1 (en) 2015-04-09
EP3052095A1 (en) 2016-08-10
KR20160070077A (ko) 2016-06-17
AU2020203044A1 (en) 2020-05-28
US11045432B2 (en) 2021-06-29

Similar Documents

Publication Publication Date Title
BR112016007328A2 (pt) composições oftálmicas baseadas em epinefrina para administração intraocular e métodos para fabricar as mesmas
BR112019000494A2 (pt) 3-metil pirazinas 2,5-dissubstituídas e 3-metil pirazinas 2,5,6-trissubstituídas como inibidores de shp2 alostéricos
BR112018005349A2 (pt) preparação farmacêutica de anticorpo anti-pd-1 estável e sua aplicação em medicamentos
EA201690713A1 (ru) Гетероциклические соединения и их применения
BR112018017172A2 (pt) anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau
BR112017008157A2 (pt) polipeptídeos de fgf-21 modificados e usos dos mesmos
BR112018077457A2 (pt) composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
EA201690753A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
BR112015028152A2 (pt) inibidores de acc e usos dos mesmos
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
EA201591661A1 (ru) Пептиды и композиции для лечения повреждений суставов
BR112018072539A2 (pt) composições de epinefrina de administração aumentada
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
BR112017015580A2 (pt) composição de limpeza para lavagem de louça, e, método para formar uma composição de limpeza para lavagem de louça
WO2014153009A3 (en) Thiosaccharide mucolytic agents
EA202090683A3 (ru) Способы и композиции для лечения рака
BR112016001544A8 (pt) composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
PH12014502352A1 (en) Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
CR20150637A (es) Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
BR112015031417A8 (pt) forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: HARROW IP, LLC (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2690 DE 26-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.